Drugs / BI 765845
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06139341 | Jul → Dec 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06139315 | Jun 2022 → Jun 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06139328 | Dec 2023 → Sep 2025 | myocardial infarction | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06139315 ↗ |
| Route | Intravenous | “following intravenous administration of single rising doses” NCT06139315 ↗ |